Related Experiment Video
Updated: Jun 6, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Very late stent thrombosis and antineoplastic therapy
Michael Ghalchi1, Thomas Chengot, Kevin Marzo
1Department of Cardiology, Winthrop University Hospital, Mineola, NY 11501, USA. mghalchi@yahoo.com
The Journal of Invasive Cardiology
|December 4, 2010
Summary
Patients with drug-eluting stents (DES) undergoing cancer treatment face increased risks of very late stent thrombosis. Managing cardiac and oncologic therapies requires careful balance to prevent life-threatening complications.
Area of Science:
- Cardiology and Oncology
- Interventional Cardiology
- Oncologic Therapeutics
Background:
- Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is common for coronary artery disease.
- Aging populations with coronary artery disease are increasingly likely to develop malignancies.
- Interactions between cardiac and oncologic conditions and their treatments pose significant risks.
Observation:
- Patients with prior PCI and DES are vulnerable to complications when diagnosed with cancer.
- Acquired prothrombotic states associated with cancer therapies can increase thrombosis risk.
- Balancing antithrombotic and bleeding risks is critical in these complex patients.
Findings:
- Highlighting potential risks of very late stent thrombosis in patients with DES and cancer.
- Examining interactions between cancer, its treatments, and cardiovascular therapies.
- Reviewing cases of very late stent thrombosis following PCI with first and second-generation DES.
Implications:
- Emphasizes the need for multidisciplinary management of patients with comorbid cardiac and oncologic conditions.
- Underscores the importance of careful consideration of drug-eluting stent thrombosis risks in cancer patients.
- Informs clinical practice regarding the management of patients with coronary artery disease and malignancy undergoing PCI.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:27Pulmonary Embolism III: Nursing Management
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:23Peripheral Artery Disease V: Postoperative Nursing Management
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...